Aardvark Therapeutics, Inc. (AARD) stock
Close on Nov 13, 2026Market cap $29.11MP/E –Yield –
Earnings
Aardvark Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Aardvark Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 22, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 13, 2026before the open | – | – | -$0.88 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026after the close | – | – | -$0.66 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 23, 2026after the close | – | – | -$0.81 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025after the close | – | – | -$0.75 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025after the close | – | – | -$0.66 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Aardvark Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Aardvark Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Aardvark Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- News
- Results
- News
- Results
- Results
- News
- News
- News
- News
- News
- News
See a number that looks wrong?